Antiangiogenic Therapy for Dogs with Measurable Soft Tissue Sarcomas

Animal Cancer Institute Studies

Since its inception the Animal Cancer Institute and its Network of veterinary oncologists have offered cutting edge treatment options. The Animal Cancer Institute Network is based in Washington, DC and extends across the United States with sites in California, Connecticut, Florida, Maryland, Massachusetts, New Jersey, New York, Ohio, Texas, Virginia and Washington .

It is the goal of the Animal Cancer Institute to provide more effective and less toxic options for the treatment of cancer. Collaboration with the pharmaceutical industry allows these options to be provided, in many cases, at substantially reduced costs. For more information on the therapeutic diet clinical study for cats with lymphoma, and the Animal Cancer Institute, visit our website at: www.animalcancerinstitute.com. 

The Animal Cancer Institute, LLC

Cutting edge options for cancer

C. Khanna DVM, PhD, DACVIM

T. Rusk DVM

Study Monitor– Kate Cadorette

Phone: 202-363-7300 Fax: 202-363-7126

Email: kcadorette@animalcancerinstitute.com

You may register your clinic to receive electronic updates on trials available to your clients. Registration for eTrial Updates is available at our website, www.animalcancerinstitute.com. 

Trial eligibility criteria include:

• client owned pet dogs

• measurable, histologically confirmed soft tissue sarcomas, not including hemangiosarcomas

• tumors must be accessible for histopath collection and objective measurement using direct caliper measurement, ultrasound, radiographs or CT/MRI scan.

• favorable clinical performance status at entry (expected to remain clinically stable for 30 days).

• no previous exposure to antiangiogenic therapies

• no chemotherapy within 14 days of trial entry

• no radiation therapy administered within 21 days of trial entry

• corticosteroids and non-steroidal anti-inflammatory agents ok to continue if patient has been receiving for >14 days at time of study entry

Trial Support/Funding Includes:

• Antiangiogenic peptide provided at no charge

• Biopsy (as required at trial initiation, date of first objective response and date of relapse)

• MRI at study entry, and every 3 months through Day 180 for selected patients

All patients must be evaluated and treated through a participating Animal Cancer Institute Network site, monthly.

Diagnostic and staging tests may be performed at any veterinary hospital within 10 days of initiation (full serum chemistry, CBC, U/A and thoracic radiographs).

Dogs will receive a supply of medication for in-home, daily subcutaneous injection or will be treated at a representative clinic every 14 days with a depot injection. Continued therapy will be available pending response to therapy.

All examination, tumor imaging and other diagnostic costs are patient’s responsibility.

Cases which relapse or are refractory following >30 days on antiangiogenic therapy will be eligible to receive open label gemcitabine therapy. Gemcitabine will be provided at no charge – all other costs associated with drug examination and drug administration will be owner responsibility. Assessment of response will be made following the first cycle of therapy and consideration for a 

2nd cycle will be made based on patient response.

For more information please contact Kate Cadorette at the Animal Cancer Institute (202-363-7300) or see our website at www.animalcancerinstitiute.com.